



Mumps NP (5E3): sc-57919

BACKGROUND

Mumps (epidemic parotitis) is a human viral disease that causes fever and painful swelling of the salivary glands, specifically the parotid gland. Mumps symptoms are usually not as severe in children as in teenagers and adults. Developments such as infertility or subfertility can occur, but are rare. The most common preventative measure against Mumps is immunization with a Mumps vaccine. Before the introduction of a vaccine, Mumps was a common childhood disease worldwide; it is still a significant health threat in the third world. The disease is caused by a negative-sense single-stranded RNA paramyxovirus, spread by saliva droplets or subsequent contact with objects contaminated with infected saliva. Virions are enveloped with fusion and attachment proteins emerging as spikes on the virion surface. The incubation period for Mumps is 15-24 days, with a median of 19 days before symptoms occur, which reflects its practicality as an epidemic inducing disease. The nucleoprotein of the Mumps virus, also known as a nucleocapsid, is the basic architecture of the virus, comprised of a core of nucleic acid captured in a protein coat. Specific antigens expressed on Mumps nucleoproteins may aid in the identification of this virus.

REFERENCES

- Hayashi, T., Hayashi, K., Maeda, M. and Kojima, I. 1997. Calcium spirulan, an inhibitor of enveloped virus replication, from a blue-green alga *Spirulina platensis*. *J. Nat. Prod.* 59: 83-87.
- Schlegel, M., Osterwalder, J.J., Galeazzi, R.L. and Vernazza, P.L. 1999. Comparative efficacy of three Mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. *BMJ* 319: 352.
- Shinefield, H., Black, S., Thear, M., Coury, D., Reisinger, K., Rothstein, E., Xu, J., Hartzel, J., Evans, B., Digilio, L., Schedel, F., Brown, M.L. and Kuter, B. 2006. Safety and immunogenicity of a Measles, Mumps, Rubella and Varicella vaccine given with combined *Haemophilus influenzae* Type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. *Pediatr. Infect. Dis. J.* 25: 287-292.
- Lieberman, J.M., Williams, W.R., Miller, J.M., Black, S., Shinefield, H., Henderson, F., Marchant, C.D., Werzberger, A., Halperin, S., Hartzel, J., Klopfer, S., Schedel, F. and Kuter, B.J. 2006. The safety and immunogenicity of a quadrivalent Measles, Mumps, Rubella and Varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. *Pediatr. Infect. Dis. J.* 25: 615-622.
- Dominguez, A., Plans, P., Costa, J., Torner, N., Cardenosa, N., Batalla, J., Plasencia, A. and Salleras, L. 2006. Seroprevalence of Measles, Rubella, and results of a cross-sectional study. *Eur. J. Clin. Microbiol. Infect. Dis.* 25: 310-317.
2006. Notice to readers: updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for the control and elimination of Mumps. *MMWR Morb. Mortal. Wkly. Rep.* 55: 629-630.
- Gorman, C. 2006. How Iowa got the Mumps. *Time* 167: 91.
- Santak, M., Kosuti-Gulija, T., Tesovi, G., Ljubin-Sternak, S., Gjenero-Margan, I., Betica-Radi, L. and Forci, D. 2006. Mumps virus strains isolated in Croatia in 1998 and 2005: Genotyping and putative antigenic relatedness to vaccine strains. *J. Med. Virol.* 78: 638-643.

SOURCE

Mumps NP (5E3) is a mouse monoclonal antibody raised against recombinant Mumps NP.

PRODUCT

Each vial contains 100 µg IgG_{2a} in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Mumps NP (5E3) is recommended for detection of Mumps NP, recombinant yeast-derived Mumps NP and native nucleoprotein in Mumps virus-infected Vero cells by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500); non cross-reactive with Measles NP.

Molecular Weight of Mumps NP: 58 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Immunofluorescence: use goat anti-mouse IgG-FITC: sc-2010 (dilution range: 1:100-1:400) or goat anti-mouse IgG-TR: sc-2781 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.